Abstract:Defining the progression of blood biomarkers of Alzheimer’s disease (AD) is essential for targeting treatments in patients most likely to benefit from early intervention. We delineated the temporal ordering of blood biomarkers a decade prior to the onset of AD symptoms in participants in the Baltimore Longitudinal Study of Aging. We show that increased astrocyte reactivity, assessed by elevated glial fibrillary acidic protein (GFAP) levels is an early event in the progression of blood biomarker changes in preclinical AD. In AD-converters who are initially cognitively unimpaired (N=158, 377 serial plasma samples), higher plasma GFAP levels are observed as early as 10-years prior to the onset of cognitive impairment due to incident AD compared to individuals who remain cognitively unimpaired (CU, N=160, 379 serial plasma samples). Plasma GFAP levels in AD-converters remain elevated 5-years prior to and coincident with the onset of cognitive impairment due to AD. In participants with neuropathologically confirmed AD, plasma GFAP levels are elevated relative to cognitively normal individuals and intermediate in those who remain cognitively unimpaired despite significant AD pathology (asymptomatic AD). Higher plasma GFAP levels at death are associated with greater severity of both neuritic plaques and neurofibrillary tangles. In the 5XFAD transgenic model of AD, we observed greater GFAP levels in the cortex and hippocampus of transgenic mice relative to wild-type prior to the development of cognitive impairment. Reactive astrocytosis, an established biological response to neuronal injury, may be an early initiator of AD pathogenesis and a promising therapeutic target.

What problem does this paper attempt to address?

The paper aims to address the issue of early diagnosis and therapeutic intervention for Alzheimer's disease (AD). Specifically, the researchers attempt to determine the temporal sequence of plasma biomarkers during the disease progression by analyzing changes in these biomarkers, particularly the astrocyte reactivity marker—glial fibrillary acidic protein (GFAP). This is to identify the patient groups most likely to benefit from early intervention within 10 years before symptom onset. Additionally, the study explores the relationship between these biomarkers and AD pathological features, as well as their potential as therapeutic targets. The study found that elevated GFAP levels are a significant event in the early plasma biomarker changes of AD, which can be observed 10 years before the onset of cognitive impairment. This suggests that astrocyte reactivity may be one of the early initiating factors in the pathogenesis of AD and could potentially become a target for therapeutic intervention.

Longitudinal progression of blood biomarkers reveals a key role of astrocyte reactivity in preclinical Alzheimer’s disease